**Blood RNA and Protein Biomarkers Are Associated with Vaping and Dual use and Prospective Health Outcomes**

Andrew Gregory[1], Zhonghui Xu[1], Katherine Pratte[2], Seth Berman[1], Robin Lu[1], Rahul Suryadevara[1], Robert Chase[1], Jeong H. Yun[1,3], Aabida Saferali[1], Craig P. Hersh[1,3], Edwin K. Silverman[1,3], Russell P. Bowler[4], Laura E. Crotty Alexander[5,6], Adel Boueiz[1,3*], Peter J. Castaldi[1,7*]

[1]Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; [2]Department of Biostatistics, National Jewish Health, Denver, CO; [3]Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; [4]Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO; [5]Division of Pulmonary, Critical Care, Physiology and Sleep Medicine, University of California San Diego (UCSD), La Jolla, CA; [6]Pulmonary Critical Care Section, Veterans Affairs (VA) San Diego Healthcare System, La Jolla, CA; [7]Division of General Medicine and Primary Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

* Equal contribution

**Corresponding Author:** Peter J. Castaldi, MD, MSc, Channing Division of Network Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115, Email: repjc@channing.harvard.edu

**Authors' email addresses:** Andrew Gregory (andrew.gregory@channing.harvard.edu), Zhonghui Xu (zhonghui.xu@channing.harvard.edu), Katherine Pratte (PratteK@njhealth.org), Seth Berman (seth.berman@channing.harvard.edu), Robin Lu (robin.lu@channing.harvard.edu), Rahul Suryadevara (rahul.suryadevara@channing.harvard.edu), Robert Chase (robert.chase@channing.harvard.edu), Jeong H. Yun (jeong.yun@channing.harvard.edu), Aabida Saferali (aabida.saferali@channing.harvard.edu), Craig P. Hersh (craig.hersh@channing.harvard.edu), Edwin K. Silverman (ed.silverman@channing.harvard.edu), Russell P. Bowler (BowlerR@njhealth.org), Laura E. Crotty Alexander (lca@ucsd.edu), Adel Boueiz (adel.boueiz@channing.harvard.edu), Peter J. Castaldi (peter.castaldi@channing.harvard.edu)

**Author Contributions:**

Drs. Boueiz and Castaldi had full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, had authority over manuscript preparation and the decision to submit the manuscript for publication.

*Study concept and design:* Gregory, Xu, Boueiz, Castaldi

*Acquisition, analysis, or interpretation of data:* All authors

*Drafting of the manuscript:* Gregory, Boueiz, Castaldi

*Critical revision of the manuscript for important intellectual content:* All authors

*Statistical analysis:* Gregory, Xu, Castaldi, Boueiz

*Obtained funding:* Boueiz, Castaldi, Silverman

*Study supervision:* All authors

All authors gave final approval of the version to be published.

**Funding Sources:** This work was supported by NHLBI K08HL141601, K08HL146972, K01HL157613, R01HL124233, U01 HL089897, R01 HL147326, and U01 HL089856. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.

**Competing Interests:** EKS and PJC have received grant support from GlaxoSmithKline and Bayer. JY has received institutional grant support from Bayer and personal fees from Bride Biotherapeutics outside the submitted work.

**Manuscript Word Count: 3,702**

**Keywords:** biomarkers, vaping, ENDS, e-cigarettes, smoking, genomics

**Abstract (250 words)**

**Background:** Electronic nicotine delivery systems (ENDS) are driving a vaping epidemic. Identifying biomarkers of vaping and dual use (concurrent vaping and smoking), will facilitate studies of the health effects of vaping.

**Research Question:** Are there blood transcriptomic and proteomic biomarkers of vaping and dual use? Are those biomarkers associated with clinically relevant prospective health outcomes, either singly or in combination?

**Study Design and Methods:** This study is an association analysis in an observational cohort obtained via convenience sampling. We studied 3,892 COPDGene study participants with blood transcriptomics and/or plasma proteomics data according to their self-reported current vaping and smoking behavior. Biomarkers of vaping and dual use were identified through differential expression analysis and related to prospective health events over six years of follow-up. To assess the predictive accuracy of multi-biomarker panels, we constructed predictive models for vaping and smoking categories and prospective health outcomes.

**Results:** We identified 3 transcriptomic and 3 proteomic associations with vaping, and 90 transcriptomic and 100 proteomic associations to dual use. Many of these vaping or dual use biomarkers were significantly associated with prospective health outcomes, such as FEV1 decline (3 transcripts and 62 proteins), overall mortality (18 transcripts and 73 proteins), respiratory mortality (2 transcripts and 23 proteins), respiratory exacerbations (13 proteins) and incident cardiovascular disease (24 proteins). Multimarker models showed good performance discriminating between vaping and smoking behavior and produced informative, modestly powerful predictions of future FEV1 decline, mortality and respiratory exacerbations.

**Conclusion:** Vaping and dual use are associated with RNA and protein blood-based biomarkers that are also associated with adverse health outcomes.

**Introduction**

The high prevalence of electronic cigarette use (vaping) among both adolescents[1] and

adult cigarette smokers[2] is a major public health concern. Electronic cigarettes, also referred to

as electronic nicotine delivery systems (ENDS), were initially marketed as a means of smoking

reduction, with the hope that their effects on the health of smokers would be a net positive.

However, vaping is associated with acute respiratory symptoms[3–5] and lung injury[6,7] and is

likely to be associated with long-term adverse health effects. Vaping companies are targeting

non-smokers and young people as a profitable demographic and promoting ENDS use beyond

the population of established smokers, resulting in an ongoing epidemic of vaping in adolescents

and non-smoking adults that is clearly detrimental to public health[8–10].

The Family Smoking Prevention and Tobacco Control Act of 2009 gave the Food and

Drug Administration (FDA) regulatory oversight over tobacco products which, by the FDA

Deeming Regulation of 2016, includes ENDS. Thus, the FDA is responsible for reviewing the

safety of all ENDS products introduced to market after February 15, 2007. To facilitate this

review process, it is important to determine whether there are validated biomarkers of ENDS use

and combined use of ENDS and cigarettes (dual use). While biomarkers of vaping and dual use

have been reported, few if any vaping biomarkers have been assessed for their association to

prospective health outcomes, and the predictive performance of multi-biomarker panels has not

been assessed. In this paper, the term biomarker refers to molecular measurements tested for

association to vaping or smoking exposure, which we distinguish from validated biomarkers in

which a specific association has been demonstrated in multiple studies. Validated biomarkers

that are also predictive of prospective health events can be considered for use as surrogate

outcomes in safety and health assessments[11,12] which would be a useful tool for evaluating

the health effects of an increasingly diverse array of ENDS products. Thus, the goal of this study

is to establish a set of candidate biomarkers for future validation and further study as potential

surrogate outcomes.

We hypothesized that vaping and dual use are associated to multi-omic biomarkers, and

that a subset of these biomarkers would be associated with the development of pulmonary and

cardiovascular disease. We conducted high throughput transcriptomic and proteomic analyses

that identified over one hundred biomarkers associated with vaping and dual use in a cohort of

adult current and former smokers in the COPDGene study. We tested these biomarkers for

association with prospective spirometric changes, mortality, and incident cardiovascular disease,

identifying dozens of significantly associated biomarkers. We also investigated the extent to

which multimarker panels can predict vaping and smoking status and the development of

prospective health outcomes.

**Methods**

*Study description*

The COPDGene study recruited 10,198 non-Hispanic White and Black smokers with at

least 10 pack-years of lifetime cigarette smoking history at 21 U.S. clinical centers

(NCT00608764, www.copdgene.org)[13] between 2007 and 2011. COPDGene obtained 5-year

follow-up and is currently obtaining 10-year follow-up of available subjects to collect

longitudinal data on study participants. 6,756 subjects completed their 5-year study visit (Visit 2)

and the 10-year study visit (Visit 3) is ongoing. Data collected includes questionnaires,

spirometry, and self-reported smoking and vaping behaviors. At visit 2, whole blood RNA

sequencing (RNA-seq), plasma protein measurements (SOMAscan version 4.0 (5.0K) assay for

human plasma), and plasma cotinine were obtained from a subset of subjects. Throughout the

study, subjects were also regularly contacted via the phone or internet as part of the COPDGene

Longitudinal Follow-up (LFU) program to assess interval events, including respiratory

exacerbations, incident comorbidities, and mortality. Definitions of respiratory exacerbations,

incident comorbidities, and mortality assessment are included in the Supplement. Written

informed consents were obtained for all subjects, and each clinical site obtained institutional

review board approval.

*Vaping and smoking groups*

Starting from Visit 2, vaping was determined by self-report including ever use, current

use, intensity, cartridge size, brand, and flavoring. The four comparison groups for biomarker

discovery (vapers, current smokers, former smokers, and dual users) were defined based on the

subjects' questionnaire responses at Visit 2. Vapers were subjects who reported using at least one

e-cigarette within the prior week and had a history of smoking tobacco cigarettes, but not within

the last 30 days. Current smokers reported current smoking with an average of at least one

cigarette per day without any e-cigarette use (current smokers). Dual users were vapers who also

reported current smoking, and former smokers were defined as those who reported a history of

smoking but did not meet criteria for current smoking or vaping. In most of the reported

analyses, former smokers are used as the reference group. Differences in baseline characteristics

between groups were assessed with Kruskal-Wallis and chi-square tests for continuous and

categorical measurements, respectively.

### RNA-sequencing

70    Total blood RNA was collected from subjects at Visit 2 in PAXgene TM Blood RNA

71    tubes from the Qiagen PreAnalytiX PAXgene Blood miRNA Kit (Qiagen, Valencia, CA). The

72    gene count data used for this analysis is available in GEO (accession number GSE158699).

73    Counts were transformed to log2 counts per million (CPM) values and quantile-normalized.

74    Additional details are included in the Supplement.

### Measurement of plasma protein biomarkers

At Visit 2, plasma samples were assayed for 4,979 proteins in 5,670 COPDGene

participants using the SOMAscan Human Plasma 5.0K assay, a multiplex aptamer-based assay

(SomaLogic, Boulder, Colorado)[14]. The standardization process included within-plate

hybridization, median signal normalization, and plate scaling and calibration of SOMAmers to

control for inter-assay variation between analytes and batch differences between plates. Inverse

normal transformation was applied to all protein measurements prior to association analysis.

### Cotinine measurements

Plasma metabolite measurements were obtained from plasma for 1,136 subjects at

COPDGene Visit 2 using the Metabolon Global Metabolomics Platform (Durham, NC,

USA)[15]. Metabolite levels were quantified as raw area counts. Plasma cotinine levels were

evaluated and missing values were assigned a level of half the lowest detected amount of

cotinine. Values were log transformed, and differences in cotinine distribution between groups

were evaluated with the Wilcoxon Rank Sum test. COPDGene metabolomic data are available in

the Metabolomics Workbench of the NIH Common Fund's National Metabolomics Data

Repository (Study ID ST001443; https://www.metabolomicsworkbench.org).

*RNA-seq differential expression and protein association analyses*

We used the limma R package (v3.38.3)[16] to test for the associations between RNA

transcripts and the vaping/smoking groups, using the former smoker group as the reference and

adjusting for age, sex, race, and library preparation batch effects. The voom function was used in

the RNA-seq analysis. Regression models for protein expression used identical covariates, with

the exception that library preparation batch effects were replaced with a variable for clinical

center. For both differential gene expression and protein association analyses, we corrected for

multiple testing with the Benjamini-Hochberg method and applied a threshold of significance of

a false discovery rate (FDR) of 10%[17]. For selected genes and proteins that were associated in

only one contrast (vaping or dual only associations), we also conducted association analyses for

the contrasts of vapers versus smokers, vapers versus dual users, and dual users versus smokers.

Gene set enrichment analysis were performed using the fast gene set enrichment analysis

(FGSEA) R package (v3.12)[18]. Further details are included in the Supplement.

*Associations of transcripts and proteins to health outcomes*

Biomarkers significantly associated with vaping or dual use were tested for association to

prospective health-related outcomes, namely change in FEV1 (absolute volume and percent

change from baseline), prospective exacerbations, all-cause and respiratory mortality, and

incident CVD. $FEV_1$ changes were computed by subtracting Visit 2 from Visit 3 $FEV_1$ values

and dividing this difference by the number of years between both visits. $FEV_1$ changes were

calculated as both absolute and relative (as a percentage of the Visit 2 measurement) values. Data

points >5 standard deviations from the mean were excluded from analysis.

The FEV1 outcomes were evaluated using multivariable linear regression models, and the

time-to-event outcomes were evaluated using Cox-proportional hazards models using Visit 2 as

the starting point. Analyses were adjusted for sex, race, and age at baseline (Visit 2). For time-to-

event outcomes baseline FEV1 % of predicted was included as a covariate. Since the sample

sizes of our vaping/smoking groups were small, these association analyses were performed in all

available COPDGene study subjects without stratifying by vaping or smoking exposure. The

FDR was controlled at 10% using the Benjamini-Hochberg method.

***Prediction modeling for vaping status and prospective health outcomes***

Predictive models using only transcript and protein biomarkers were constructed for

vaping/smoking groups and prospective health outcomes. For categorical and binary outcomes,

linear discriminant analysis (LDA) was used. For change in FEV1 models, elastic net models

were constructed. Cross-validation was used to prevent overfitting and estimate predictive

performance. Model performance was assessed by cross-validation using the Youden index

(sensitivity + specificity - 1), area under the receiver operator characteristic curve (AUROC), and

area under the precision recall curve (AUCPR) for binary outcomes. R2 was used to evaluate the

performance of change in FEV1 models. Additional details are included in the Supplement.

**<u>Results</u>**

***Baseline characteristics***

136            A visual overview of the study and data flow is included in Supplemental Figures 1 and

2. There were 51 and 77 subjects reporting current vaping only or dual use, respectively, at the

COPDGene second study visit. Differences in baseline characteristics of these groups along with

the current and former smoker groups are reported in Table 1. The large majority of subjects in

the vaping group (80%) reported vaping at least once a day. The dual user group reported lighter

vaping on average, with only 42% reporting daily vaping, and their pack-years exposure to

combustible tobacco was similar to the current smoker group. FEV1 % of predicted values were

comparable for all groups. Biochemical confirmation of nicotine exposure via analysis of plasma

cotinine levels in 853 subjects demonstrated elevated cotinine levels in the vaping, dual use, and

smoking groups relative to the former smokers group (Figure 1, Wilcoxon rank sum test $p < 0.005$

for all comparisons). A subset of the former smoker group had elevated levels of nicotine that

could be due to use of nicotine replacement therapy, secondhand exposure to tobacco smoke or

e-cigarette aerosols, or unreported smoking or vaping.

***Blood RNA-seq associations with vaping and dual use***

A total of 18,303 genes were tested for differential expression analysis of vapers, dual

users, and current smokers using the former smoker group as the reference group. The top results

from each analysis are shown in Table 2, and complete results are reported in Tables S1-S3. For

vapers, three significant associations were identified at an FDR of 10% (Figure 2). Two of these

genes (*LINC02470* and *NPHP1)* were expressed at a higher level in vapers than any of the other

three groups (p<0.05 for all comparisons, Table S4). The third gene, *GPR15* is one of the most

well-reported genes upregulated by smoking. This gene is also upregulated in vapers, but to a

lesser extent than in either smokers or dual users (p<0.005 for all comparisons). Gene set

enrichment analysis identified 16 significant MSigDB Hallmark pathways with the top three

processes being related to inflammation, oxidative phosphorylation, and heme metabolism

(Table 3). For all significant gene sets, enrichment was in the direction of decreased expression

in vapers compared to former smokers. Since smoking has been shown to have mixed effects on

inflammation, we compared the pattern of gene set enrichment for the Hallmark Inflammation

pathway in vapers, smokers, and dual users, and we observed that smoking and dual use show

elements of activation and repression of this gene set, the effect of vaping was more clearly

downregulation of this pathway (Supplemental Figure 3).

For dual users, 90 differentially expressed genes were identified, and 17 of these genes

were significant only in the dual user analysis. All of these 17 genes were also significantly

differentially expressed when comparing dual users to current smokers, suggesting that these

genes have a distinctive response to dual use (p<0.005 for all comparisons, Table S5). Gene set

enrichment analysis identified four significant Hallmark pathways related to heme metabolism,

oxidative phosphorylation, E2F signaling, and interferon gamma response (Table 3). Complete

results for the vaping, dual use, and smoking analyses including MSigDB Immunologic

Signature pathways are presented in Supplemental Tables S6-S8.

*Proteomic biomarker associations to vaping and dual use*

A total of 4979 SOMAscan aptamers mapping to 4,720 unique proteins were tested for

association to vaping and smoking groups. The top significantly associated proteins are shown in

Table 2 (see Table S9 for complete results), and violin plots for selected top protein biomarkers

associated with vaping or dual use are shown in Figure 3. Three protein biomarkers (EDIL3,

DPYL5, and KLK13) were significantly associated with vaping status at a 10% FDR, and

DPYL5 expression was found to be higher in vapers compared to each of the other groups

(p<0.05 for all comparisons, Table S10). One hundred protein biomarkers were associated with

dual use, with four (CXA8, Keratin 19, CSKP, and PXDC1) being significantly associated only

with dual use. All four of these proteins also showed nominal association (p<0.05) in an analysis

comparing dual users to current smokers, indicating a distinct response to dual use (Table S11).

*Comparison of biomarker associations to vaping, smoking, and dual use*

To compare the similarity of the transcriptomic and proteomic responses to each exposure, we

constructed pairwise plots of the effect sizes of all significantly associated biomarkers (Figure 4).

There was a strong positive correlation between the biomarker responses to smoking and dual

use (Pearson's r = 0.76 and 0.88 for RNA and protein, respectively), whereas the vaping

biomarker profile had low correlation to the profiles for both dual use and smoking (r between

0.23 and 0.44). Certain biomarkers (LINC02470 and DPYL5 protein) had particularly strong and

unique associations with vaping. When we compared effect sizes between RNA and proteomic

biomarkers associated with vaping and smoking, the correlation was low (r=0.11) as might be

expected given various potential sources of origin for circulating blood proteins.

*Classification Accuracy for Vaping/Smoking Behavior Using Biomarker Panels*

To determine how well RNA and protein biomarkers could classify subjects according to

their vaping/smoking behavior, we used a nested cross-validation approach to provide an

unbiased estimate of the classification performance achievable by multi-class prediction models

using linear discriminant analysis (LDA). The performance of this model is shown in Table 4,

where for each group the task is to distinguish that group from all other groups combined. The

model achieved good discrimination for current smokers (Youden index (YI) = 0.81) and former

smokers (YI = 0.80) and had statistically significant but less accurate performance for vapers (YI

= 0.53) and dual users (YI = 0.55). More detailed metrics for each pairwise contrast (Table S12)

demonstrates that the models do better in discriminating vapers from current smokers than

former smokers (YI = 0.73 and 0.50, respectively), whereas for dual user models discrimination

was better for former smokers (YI = 0.82) than current smokers (YI = 0.34), providing further

evidence of the similarity between dual use and current smoking biomarker profiles.

*Vaping and Dual Use Biomarkers and Longitudinal outcomes*

To determine whether biomarkers of vaping or dual use were associated with prospective

health-related outcomes, we tested the 92 RNA transcripts and 101 protein biomarkers associated

with vaping and/or dual use for association to multiple health outcomes in all COPDGene

subjects. Twenty-one transcripts and 88 protein biomarkers were associated with one or more of

the studied outcomes at a 10% FDR level. Of the vaping-associated biomarkers, two (KLK13

and DPYL5) were associated with loss of FEV1, and KLK13 was also associated with mortality.

Boxplots for the top four vaping or dual use proteins associated with all-cause mortality are

shown in Figure 5, and all significant biomarker associations are shown in Tables S13-S16.

We then determined whether the effect of vaping or dual use on each protein biomarker

was consistent with higher or lower risk for each adverse health outcome, and we observed that

the direction of the exposure effect was overwhelmingly towards increased risk for adverse

health events (Figure 6). Out of 246 total significant associations to health outcomes, 224 (91%)

showed concordance between the effect of vaping or dual use and the direction of association to

increased risk. Both of the vaping-associated biomarkers (KLK13 and DPYL5) showed

concordant effects for higher health risk.

To estimate the accuracy of multi-marker panels of vaping and dual use biomarkers for

predicting prospective health outcomes, we constructed predictive models for FEV1 decline, all

cause mortality, COPD exacerbations, and incident CVD using only the vaping or dual-use

associated RNA and protein biomarkers. Models using the seven vaping-associated biomarkers

alone gave non-informative predictions, but models using the 190 dual use-associated

biomarkers gave informative predictions with moderate accuracy for FEV1 decline, all-cause

mortality and respiratory exacerbations (Table 5).

*Replication of previously reported vaping biomarker associations*

A recently published review of vaping biomarkers listed 14 inflammatory and matrix

degradation protein biomarkers that had been previously associated with vaping[19]. We

examined the results from these 14 biomarkers at the RNA and protein level for association to

vaping or dual use, and we observed associations at nominal significance ($p<0.05$) for four

biomarkers (*IL1B*, ICAM1 [both RNA and protein], IL-6, and MMP9, see Table S17).

**Discussion**

Identifying validated biomarkers of vaping and dual use is an important tool both for

guiding ENDS users as to the risks of these devices and effective regulation of ENDS. This study

of established adult smokers identified significant associations of 6 and 190 blood molecular

markers with vaping and dual use, respectively. Because of the comprehensive nature of the

'omics measurements, we were able to compare overall molecular profiles of vaping, dual use,

and smoking. These analyses found that the vaping profile was substantially different from

current smoking, whereas dual use and smoking were similar but not identical. Biomarkers

associated with vaping and dual use were also associated with multiple cardiopulmonary health

outcomes, and reasonably predictive accuracy for some of these outcomes could be achieved for

models using dual use biomarkers.

A previous metabolomic biomarker study by Goniewicz et al. demonstrated that vaping is

associated with metabolomic changes, albeit at generally lower levels compared to cigarette

smokers or dual users[20]. A recent study of vapers versus non-smokers identified numerous

changes in plasma biomarkers associated with inflammation, oxidative stress, and extracellular

matrix degradation[19]. A recent meta-analysis of biomarkers of ENDS versus cigarettes

reported a more favorable biomarker profile of ENDS use, though the last author of the study has

been reported to have ties to the tobacco industry[21,22]. Another systematic review also

reported reduced levels of some biomarkers in ENDS users relative to smokers, but this is not

consistent for all biomarkers(Hiler et al. 2021). By examining the correlation in biomarker

profiles for vaping, dual use, and smoking, we observed that the vaping profile is largely distinct

from both the dual use and smoking profile which are in turn highly correlated to each other. We

did however observe multiple examples of shared RNA and protein biomarkers between

smoking, vaping, and dual use, such as *GPR15, a regulator of inflammation and T-cell*

*trafficking*. We also provided independent validation for previously reported vaping or dual use

associations with *IL1B*, ICAM1, IL-6, and MMP9, all of which are known to influence

inflammation (IL-1B can induce MMP-9 expression and activity).

Both vaping and dual use are associated with diverse effects on biological pathways

related to aspects of inflammation, oxidative phosphorylation, and coagulation-related pathways.

Previous studies have also shown that long non-coding RNAs (lncRNAs) are associated with

vaping[23,24], and in our work we identified LINC02470 as a novel vaping biomarker.

LINC02470 has previously been reported to modulate Wnt-beta catenin signaling via exosomal

secretion from bladder cancer cells[25]. Because Tang et al. previously demonstrated bladder

urothelial hyperplasia in mice exposed daily to e-cigarette aerosols, the finding of LINC02470 in

the circulation of human ENDS users is highly concerning. We also identified DPYL5 as being

uniquely upregulated in vaping subjects. DPYL5 is primarily expressed in brain tissue and glial

cells, though it is also expressed at detectable levels in the gastrointestinal (GI) tract. DPYL5 is

potentially an important vaping biomarker, because it was also predictive of future loss of lung

function. To our knowledge this is the first report of DPYL5 as a specific and clinically relevant

biomarker of vaping, a finding that requires further independent validation.

Many of the biomarkers altered by vaping and dual use are also associated with risk of

adverse health events such as loss of lung function, respiratory exacerbations, and mortality. For

the overwhelming majority of biomarkers, the direction of effect of vaping and dual use was

consistent with increased health risk. This extends numerous prior observations linking vaping to

a variety of pulmonary symptoms and alterations of cardiovascular physiology[26], providing an

important link to longer term health outcomes and suggesting that some of these biomarkers may

be useful in assessing health risks of specific vaping devices and e-liquid formulations. For dual

use, a multi-marker panel of associated biomarkers achieved modest predictive accuracy for

some important outcomes. For vapers, the biomarker profile was more subtle and with our

current sample size we did not identify a sufficient number of biomarkers to enable accurate

multi-marker prediction of health outcomes.

The strengths of this study are the high-throughput approach to biomarker discovery, the

characterization of associations to prospective health events, and the use of machine learning to

assess the predictive performance of multimarker panels. Limitations include a modest sample

size of vapers and dual users and the lack of independent replication due to lack of available

cohorts with similar biomarker data and exposure characterization. Information regarding

specific vaping devices and fluids was limited and reflects the challenges posed by the rapid

evolution of vaping devices over the study period. Our findings cannot be assumed to generalize

to newer generation vaping devices which will require dedicated study, and our findings in adults

do not necessarily apply to other important groups such as adolescents.

In conclusion, this study identified over one-hundred transcriptomic and proteomic

biomarkers associated with vaping and dual use, and many of these biomarkers are also

associated with prospective cardiopulmonary health outcomes. Prediction of health outcomes

using multimarker panels can provide informative prediction with room for improvement, and

validation in independent cohorts will increase confidence in individual biomarkers and multi-

marker models. Larger-scale studies with greater power would be likely to identify additional

biomarkers that could further improve predictive model performance.

**Table 1.** Baseline characteristics of the vaping and smoking groups

| | Current smokers (n = 1,328) | Former smokers (n = 2,436) | Vapers (n = 51) | Dual users (n = 77) | P-value |
|---|---|---|---|---|---|
| Age | 59.6 (9.5) | 68.6 (11.9) | 64.6 (10.2) | 61.6 (9.9) | < 0.001 |
| Sex, % male | 50.5% | 52.0% | 39.2% | 48.1% | 0.3 |
| % Non-Hispanic Whites | 47.1% | 82.4% | 88.2% | 71.4% | < 0.001 |
| BMI | 27.2 (8.4) | 28.7 (7.6) | 29.2 (9.6) | 26.9 (7.1) | < 0.001 |
| Smoking pack-years | 41.1 (25.8) | 38.0 (29.2) | 50.1 (26.3) | 45.0 (26.3) | < 0.001 |
| $FEV_1$ (L) | 2.2 (1.1) | 2.1 (1.2) | 2.1 (1.2) | 2.1 (1.2) | < 0.001 |
| $FEV_1$, % predicted | 81.9 (28.0) | 82.0 (35.6) | 83.2 (32.7) | 76.9 (29.7) | 0.2 |
| FVC (L) | 3.1 (1.4) | 3.0 (1.4) | 3.1 (1.5) | 3.0 (1.5) | 0.02 |
| Use of e-cigarettes: | | | | | |
|     Less than once a month | NA | NA | 0.0% | 2.6% | 0.3 |
|     Less than once a week | NA | NA | 0.0% | 15.6% | 0.003 |
|     Some days (1-3 days a week) | NA | NA | 4.0% | 27.3% | < 0.001 |
|     Most days | NA | NA | 16.0% | 13.0% | 0.6 |
|     Every day | NA | NA | 80.0% | 41.6% | < 0.001 |
| Cartridge size: | | | | | |
|     0 mg | NA | NA | 8.2% | 4.0% | 0.3 |
|     6-8 mg | NA | NA | 20.4% | 16.0% | 0.5 |
|     9-12 mg | NA | NA | 14.3% | 9.3% | 0.4 |
|     13-16 mg | NA | NA | 14.3% | 6.7% | 0.2 |
|     Do not know | NA | NA | 22.5% | 52.0% | 0.001 |
|     Other | NA | NA | 20.4% | 12.0% | 0.2 |
| Number of e-cigarettes used (last 24 hours) | NA | NA | 10 (16) | 3 (10) | < 0.001 |
| Number of cartridges used/week | NA | NA | 2 (6) | 1 (1) | 0.002 |
| E-cigarette brand: | | | | | |
|     Blu | NA | NA | 4.6% | 17.4% | 0.04 |
|     Henley | NA | NA | 2.3% | 1.5% | 0.7 |
|     Joye | NA | NA | 0.0% | 2.9% | 0.3 |
|     NJOY | NA | NA | 2.3% | 8.7% | 0.2 |
|     V2 | NA | NA | 2.3% | 2.9% | 0.8 |
|     Other | NA | NA | 90.9% | 71.0% | 0.01 |
| SGRQ Symptom Score | 28.7 (40.4) | 17.9 (39.0) | 15.8 (46.3) | 43.5 (48.5) | < 0.001 |
| Respiratory exacerbation | 14.4% | 17.9% | 21.6% | 23.4% | 0.01 |
| CVD | 18.5% | 25.8% | 15.7% | 18.2% | < 0.001 |

Continuous variables are reported as medians (interquartile ranges). Categorical variables are reported as percentages. Kruskal-Wallis rank sum tests were used for continuous variables. Chi-square tests were used for categorical variables. BMI: Body mass index; CVD: Cardiovascular disease (history of stroke, heart attack, coronary artery disease, coronary artery bypass graft surgery, peripheral artery disease, and/or cardiac angina); Respiratory exacerbation: At least one respiratory exacerbation (acute worsening of respiratory symptoms that required systemic steroids and/or antibiotics) in the previous year; $FEV_1$: Forced expiratory volume in 1 second; $FEV_1$, % predicted: Observed FEV1 / Predicted FEV1 based Hankinson reference equation; FVC: Forced vital capacity; SGRQ: St. George's respiratory questionnaire score. % LAA-950: Percentage of CT low attenuation less than -950 HU at end-inspiration using Thirona software; % Segmental airway wall thickness: Percentage of the wall relative to the total bronchial area for the segmental airways. NA = Not applicable.

**Table 2.** Top 5 differentially associated genes and proteins for vapers, dual users, and current smokers.

| | Genes | | | | Proteins | | | |
|---|---|---|---|---|---|---|---|---|
| | Gene | Ensembl gene ID | Log fold change | q-value | Protein | Uniprot ID | Mean difference | q-value |
| **Vaping** | GPR15 | ENSG00000154165 | 0.90 | <0.001 | EDIL3 | O43854 | 0.52 | 0.03 |
| | NPHP1* | ENSG00000144061 | 0.79 | 0.05 | DPYL5* | Q9BPU6 | 0.62 | 0.03 |
| | LINC02470* | ENSG00000225231 | 1.37 | 0.07 | Kallikrein 13 | Q9UKR3 | 0.54 | 0.09 |
| | | | | | | | | |
| | | | | | | | | |
| **Dual use** | SEMA6B | ENSG00000167680 | 2.10 | <0.001 | Placental alkaline phosphatase | P05187 | 1.12 | <0.001 |
| | MIR124-1HG | ENSG00000253230 | 2.32 | <0.001 | PPBN | P10696 | 0.92 | <0.001 |
| | GPR15 | ENSG00000154165 | 1.71 | <0.001 | LPLC1 | Q8TDL5 | 0.88 | <0.001 |
| | LRRN3 | ENSG00000173114 | 1.59 | <0.001 | PSP-94 | P08118 | 0.88 | <0.001 |
| | CTTNBP2 | ENSG00000077063 | 1.52 | <0.001 | sICAM-5 | Q9UMF0 | 0.84 | <0.001 |
| **Current smoking** | GPR15 | ENSG00000154165 | 1.34 | <0.001 | Placental alkaline phosphatase | P05187 | 1.00 | <0.001 |
| | MIR124-1HG | ENSG00000253230 | 1.79 | <0.001 | PPBN | P10696 | 0.89 | <0.001 |
| | SEMA6B | ENSG00000167680 | 1.51 | <0.001 | PSP-94 | P08118 | 0.77 | <0.001 |
| | LRRN3 | ENSG00000173114 | 1.21 | <0.001 | LPLC1 | Q8TDL5 | 0.72 | <0.001 |
| | P2RY6 | ENSG00000171631 | 0.88 | <0.001 | PIGR | P01833 | 0.73 | <0.001 |

Differential gene expression and protein association analyses was performed for each vaping/smoking group using the former smoker group as reference and adjusting for age, sex, race and batch effects. Up to 5 significant biomarkers are shown. "Uniquely" significant biomarkers (i.e. biomarkers significant at 10% FDR for one contrast but not for any of the other contrasts) are indicated with *. Effect sizes are reported as log fold change for the RNA-seq analysis and mean difference in normalized RFU (relative fluorescence units) for the proteomics analysis. Q-values calculated using the Benjamini-Hochberg procedure implemented in the p.adjust function in R.

**Table 3.** Top 5 significant (adjusted P-values < 0.1) MSigDB Hallmark pathways from differential gene expression analyses for the vaping and smoking groups.

| | MSigDB Hallmark pathway | Pathway ID | Number of genes | NES | Adjusted P-value |
|---|---|---|---|---|---|
| **Vaping** | Inflammatory Response | M5932 | 163 | -4.10 | $6.3 \times 10^{-10}$ |
| | Oxidative Phosphorylation | M5936 | 200 | -4.01 | $2.8 \times 10^{-9}$ |
| | Heme Metabolism | M5945 | 195 | -3.82 | $2.7 \times 10^{-8}$ |
| | TNF-α Signaling via NF-kB | M5890 | 179 | -3.85 | $3.7 \times 10^{-8}$ |
| | Complement | M5921 | 171 | -3.50 | $4.0 \times 10^{-7}$ |
| | | | | | |
| **Dual Use** | Heme Metabolism | M5945 | 195 | -5.53 | $3.9 \times 10^{-17}$ |
| | Oxidative Phosphorylation | M5936 | 200 | -3.70 | $1.7 \times 10^{-7}$ |
| | E2F Targets | M5925 | 199 | -3.69 | $2.0 \times 10^{-7}$ |
| | Interferon gamma response | M5913 | 194 | -2.90 | $1.4 \times 10^{-4}$ |
| | | | | | |
| | | | | | |
| **Smoking** | Heme Metabolism | M5945 | 195 | -8.68 | $1.2 \times 10^{-48}$ |
| | MYC Targets V1 | M5926 | 200 | 3.33 | $6.1 \times 10^{-6}$ |
| | Estrogen Response Late | M5907 | 145 | -2.89 | $2.2 \times 10^{-4}$ |
| | Xenobiotic Metabolism | M5934 | 151 | -2.86 | $3.2 \times 10^{-4}$ |
| | Epithelial mesenchymal transition | M5930 | 129 | -2.86 | $3.8 \times 10^{-4}$ |

Gene set enrichment analysis (GSEA) was performed using the results from the differential expression analysis comparing vapers, dual users, or current smokers to former smokers. Genes were ranked for enrichment analysis by log fold change. The top 5 results from the MSigDB Hallmarks gene sets are shown ordered by p-value. The "number of genes" column is the number of genes associated with the GSEA pathway that could be mapped to the differential expression results. Abbreviations: NES = normalized enrichment score. UV= ultraviolet light.

**Table 4.** Multi-class prediction of vaping and smoking groups using multi-omic biomarkers

| | Integrated RNA-seq and proteomic data | | | |
|---|---|---|---|---|
| | Current smokers | Former smokers | Vapers | Dual users |
| AUROC | 0.94 | 0.94 | 0.71 | 0.71 |
| AUPRC | 0.85 | 0.97 | 0.06 | 0.04 |
| Youden index | 0.81 | 0.80 | 0.53 | 0.55 |
| Linear discrimination analysis models were used to classify vaping and smoking groups. For each group, LDA models are constructed to distinguish that group from the other three using 10-fold nested cross validation (CV) to estimate performance. Abbreviations: AUROC = Area under the receiving operating characteristic curve; AUPRC = Area under the precision-recall curve. The Youden Index (YI) metric was used to summarize the model performance at the optimal cutoff on the area under the receiver operating curve. | | | | |

**Table 5.** Performance metrics of prediction models for prospective health outcomes.

| Biomarker Panel | Outcome | Sample size (events) | AUROC | AUPR | Youden Index | R2 |
|---|---|---|---|---|---|---|
| Dual Use Biomarkers | Δ FEV1 (ml/yr) | 642 | NA | NA | NA | 0.08 |
| | Δ FEV1 (% of baseline) | 642 | NA | NA | NA | 0.17 |
| | Overall mortality | 2388 (246) | 0.68 | 0.38 | 0.36 | NA |
| | Exacerbation >= 1 | 2231 (811) | 0.63 | 0.51 | 0.25 | NA |
| | Incident CVD | 1700 (183) | 0.68 | 0.34 | 0.36 | NA |
| Prediction models for the indicated outcomes were constructed using elastic net for change in FEV1 models and linear discriminant analysis for binary outcomes. Δ FEV1 (ml/yr) = (FEV1 at visit 3 - FEV1 at visit 2) / years between visits. Δ FEV1 (% of baseline) = Δ FEV1 (ml/yr) / FEV1 at visit 2. Exacerbation = 1 if subjects reported one of more exacerbation over the follow-up period after visit 2 and 0 otherwise. Incident CVD = 1 if subject reported new diagnosis of CVD after visit 2, and subjects with existing CVD at visit 2 were excluded. AUROC = area under the receiver operator characteristic. AUPR = area under the precision-recall curve. R2 = r-squared. |||||||

## Figure Legends:

**Figure 1. Plasma cotinine levels by vaping/smoking group.** In a subset of subjects, plasma metabolomics data was measured using the Metabolon Global Metabolomics Platform. Violin plots of log-transformed cotinine raw area counts are shown. Cotinine levels are significantly higher in all three groups relative to FS (Wilcoxon rank sum $p < 0.005$ for all three comparisons). FS = former smokers. CS = current smokers.

**Figure 2. Significantly associated vaping RNA biomarkers.** Three RNA biomarkers were significantly associated at 10% FDR in the analysis comparing vapers to former smokers. *NPHP1* and *LINC02470* were significantly associated in the vaping but not the smoking or dual use comparison to former smokers. *GPR15* is significantly elevated in all three groups relative to former smokers, but its expression is relatively lower in vapers relative to dual users and current smokers ($p<0.005$ for all comparisons).

**Figure 3. Top protein biomarkers significantly associated with vaping or dual use.** The distribution of the top significantly associated protein biomarkers in the analysis of vapers or dual users versus former smokers. DPYL5 is significantly elevated in vapers relative to all other vaping/smoking groups ($p<0.005$). KLK13 is significantly associated with vapers, dual users, and current smokers when compared to former smokers. s-ICAM5 and Secretoglobin family member 3A member 1 were significantly associated with dual users and current smokers but not vapers when compared to former smokers.

**Figure 4. Correlation of biomarker responses between vapers, dual users, and current smokers.** Comparison of the biomarker association profiles demonstrates that while the dual user and current smoker profiles are very similar, the vaping biomarker profile is more distinct. For the RNA and protein biomarker analysis of vaping/smoking groups versus former smokers, the effect sizes for each pair of comparisons were plotted and the Pearson correlation of effect sizes was calculated. In each pairwise comparison, only biomarkers significant in at least one of analyses were analyzed. In row A, vaping-associated RNA biomarker effects are compared to current smoker effects (left), dual user effects (middle), and then dual user and current smoker effects are compared (right). In row B, the corresponding protein biomarker effects are compared.

**Figure 5. Top protein vaping and dual use biomarkers significantly associated with overall mortality.** The dual use-associated proteins Growth hormone receptor, MIC-1, and HE4 were significantly associated with overall mortality. KLK-13 was the only vaping associated biomarker that was also associated mortality. All associations were significant at a false discovery rate of 10%.

**Figure 6. Concordance analysis of biomarker associations to vaping/dual use and adverse health outcomes.** For protein biomarkers that were significantly associated with at least one health outcome and vaping (n=2) or dual use (n=86), we plotted the effect of the exposure (vaping or dual use) against the effect with respect to the health outcome. Since some biomarkers were significantly associated with multiple health outcomes, the total number of analyzed

associations was 246. The top panel shows the relationship between exposure effect and change FEV1 (ml/yr) where each of the 107 associations was concordant for loss of FEV1. Change in FEV1 is calculated as visit 3 value - visit 2 value, meaning negative values indicate loss of lung function. The bottom panel shows the relationship between exposure effect and hazard ratio for all cause mortality, respiratory mortality, exacerbations, or incident cardiovascular disease. 117 of 139 associations were concordant for higher health risk. Exposure effect is the beta coefficient from the dual use versus former smokers analysis, except for DPYL5 and KLK13 which is from the vapers versus former smokers analysis.

**References**

Gentzke AS, Wang TW, Jamal A, *et al.* Tobacco Product Use Among Middle and High School Students - United States, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:1881–8.

Mayer M, Reyes-Guzman C, Grana R, *et al.* Demographic Characteristics, Cigarette Smoking, and e-Cigarette Use Among US Adults. *JAMA Netw Open* 2020;**3**:e2020694.

Li D, Sundar IK, McIntosh S, *et al.* Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2. Tobacco Control. 2019;:tobaccocontrol – 2018. doi:10.1136/tobaccocontrol-2018-054694

Yao T, Max W, Sung H-Y, *et al.* Relationship between spending on electronic cigarettes, 30-day use, and disease symptoms among current adult cigarette smokers in the U.S. *PLoS One* 2017;**12**:e0187399.

St Helen G, Eaton DL. Public Health Consequences of e-Cigarette Use. *JAMA Intern Med* 2018;**178**:984–6.

Smith ML, Gotway MB, Crotty Alexander LE, *et al.* Vaping-related lung injury. *Virchows Arch* 2021;**478**:81–8.

Cherian SV, Kumar A, Estrada-Y-Martin RM. E-Cigarette or Vaping Product-Associated Lung Injury: A Review. *Am J Med* 2020;**133**:657–63.

Hammond D, Reid JL, Rynard VL, *et al.* Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. *BMJ* 2019;**365**:l2219.

Miech R, Johnston L, O'Malley PM, *et al.* Trends in Adolescent Vaping, 2017–2019. *N Engl J Med* 2019;**381**:1490–1.

Miech R, Johnston L, O'Malley PM, *et al.* Adolescent vaping and nicotine use in 2017-2018 - U.s. national estimates. *N Engl J Med* 2019;**380**:192–3.

Aronson JK. Research priorities in biomarkers and surrogate end-points. *Br J Clin Pharmacol* 2012;**73**:900–7.

FDA-NIH Biomarker Working Group. *BEST (Biomarkers, EndpointS, and Other Tools) Resource*. Food and Drug Administration (US) 2016.

Regan EA, Hokanson JE, Murphy JR, *et al.* Genetic epidemiology of COPD (COPDGene) study design. *COPD* 2010;**7**:32–43.

Gold L, Ayers D, Bertino J, *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* 2010;**5**:e15004.

Gillenwater LA, Kechris KJ, Pratte KA, *et al.* Metabolomic Profiling Reveals Sex Specific Associations with Chronic Obstructive Pulmonary Disease and Emphysema. *Metabolites* 2021;**11**. doi:10.3390/metabo11030161

Ritchie ME, Phipson B, Wu D, *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;**43**:e47.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc* 1995;**57**:289–300.

Gennady Korotkevich, Vladimir Sukhov, Nikolay Budin, Boris Shpak, Maxim N. Artyomov, Alexey Sergushichev. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. biorxiv. 2021. doi:10.1101/060012

Singh KP, Lawyer G, Muthumalage T, *et al.* Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries. *ERJ Open Res* 2019;**5**. doi:10.1183/23120541.00182-2019

Goniewicz ML, Smith DM, Edwards KC, *et al.* Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. *JAMA Netw Open* 2018;**1**:e185937.

Akiyama Y, Sherwood N. Systematic review of biomarker findings from clinical studies of electronic cigarettes and heated tobacco products. Toxicology Reports. 2021;**8**:282–94. doi:10.1016/j.toxrep.2021.01.014

Neil Sherwood. TobaccoTactics. 2020.https://tobaccotactics.org/wiki/neil-sherwood/ (accessed 26 Jun 2022).

Tommasi S, Caliri AW, Caceres A, *et al.* Deregulation of Biologically Significant Genes and Associated Molecular Pathways in the Oral Epithelium of Electronic Cigarette Users. *Int J Mol Sci* 2019;**20**. doi:10.3390/ijms20030738

Kaur G, Singh K, Maremanda KP, *et al.* Differential plasma exosomal long non-coding RNAs expression profiles and their emerging role in E-cigarette users, cigarette, waterpipe, and dual smokers. *PLoS One* 2020;**15**:e0243065.

Huang C-S, Ho J-Y, Chiang J-H, *et al.* Exosome-Derived LINC00960 and LINC02470 Promote the Epithelial-Mesenchymal Transition and Aggressiveness of Bladder Cancer Cells. *Cells* 2020;**9**. doi:10.3390/cells9061419

Bozier J, Chivers EK, Chapman DG, *et al.* The Evolving Landscape of e-Cigarettes: A Systematic Review of Recent Evidence. *Chest* 2020;**157**:1362–90.